Skip to main content
Close

Industry Partners

PHSA’s Technology Development Office acts as a networking resource to connect industry with the research and technology expertise at all PHSA agencies. 

The PHSA Technology Development Office (TDO) helps manage interactions between scientists, clinicians and industry partners to promote the development of relationships and to explore opportunities for translating discoveries into innovations.

Industry partners are invited to contact TDO for any of the following:

Licensing

TDO can assist in connecting industry partners with new technologies developed at the BC Cancer Agency and other PHSA agencies. Please contact us for more information.

Currently, technologies available for licensing include:

‎ABySS software is a novel parallel algorithm to assemble short sequencing data. 


Genome Research Abstract

Flintbox file INV-10-004

 

Using a novel approach to biomarker discovery that used the same subject as his/her own control to identify elevated proteins in the pulmonary venous effluent draining the tumor vascular bed compared to matched systemic arterial blood, we have identified Connective Tissue-Activating Peptide III (CTAP III) as a novel blood-based biomarker to detect pre-clinical lung cancer up to 29 months before clinical diagnosis. Furthermore, CTAP III was found to decrease in patients who are cured by surgery but remains elevated in those who later developed recurrent disease. 


Lung cancer is the most common cause of cancer deaths worldwide with more than 1.2 million people dying of the disease annually. The overall 5-year survival is only 16%. However, if lung cancer is diagnosed and treated in the pre-invasive and early invasive stage (Stage 0/IA), the 5-year survival is 70-90%. In patients with larger lung cancer and those with spread to regional lymph nodes within the lung, surgical resection still offers a chance of cure but 50% will develop tumour recurrence despite what appears to be complete surgical removal. Adjuvant chemotherapy improves survival in these patients. However, to cure one additional patient over and above surgical resection alone, it is necessary to treat 10 to 20 patients. For patients that do not benefit from chemotherapy, side-effects negatively influence the quality-of-life and are associated with a 1% risk of fatal toxicity. A promising strategy to reduce lung cancer mortality is to detect lung cancer early and offer adjuvant chemotherapy only to those with microscopic residual disease after surgical resection.    Currently, there are no diagnostic tests available to reliably detect lung cancer at the earliest pre-clinical stage or monitor patient outcome after treatment with curative  intent.  CTAP III is a novel blood-based biomarker with the potential to detect pre-clinical lung cancer up to two years prior to clinical presentation.

 

Researchers at the British Columbia Cancer Agency developed Irinophore C™, a novel nano-formulation of the chemotherapy agent irnotecan, commonly used in the treatment of colon cancer. ‎


Flintbox file P2282

 

A series of novel loxP spacer sites with the potential to be developed into a novel platform for powerfully expanding the potential of the routinely used Cre-LoxP system. 


Flintbox file INV 30061

Patient transport between hospitals in different cities is a frequent requirement where very specialized medical procedures e.g. critical care interventions such extracorporal life support (ECLS) are restricted to regional centers. Patient movements under these circumstances is complex: Not only has the patient to be moved, but also all of the life support equipment such as ECLS circuit, ventilator, IV, etc., without interruption of function. All this equipment has to be placed on top of a stretcher, under tight space limitations, so that everything can fit into an ambulance, helicopter and/or aircraft but still be accessible to care-givers. 


The development of ECLS technology has enabled transport of ECLS-dependent patients in who are in need of an intervention such as transplantation which is only available elsewhere. Until today, there was no commercially available transport solution for ECLS-dependent patients: each center that has transported patients has developed their own system or one-off creation.


Flintbox file P4214 

Research materials

TDO can help industry partners enter into a Material Transfer Agreement (MTA) to receive BC Cancer Agency research materials. Please contact us for more information.

We can also connect you to the right person if you're interested in receiving research materials developed at another PHSA agency.

Discussing opportunities

Sponsored Research and Collaborative Research Agreements are the first step to developing valuable partnerships and intellectual property. If you'd like to discuss a potential collaboration or obtain more information about a researcher at the BC Cancer Agency or PHSA, please contact us.

If your discussions include proprietary or confidential information, TDO can prepare and execute a Confidential Disclosure Agreement (CDA) on behalf of PHSA.

SOURCE: Industry Partners ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © Provincial Health Services Authority. All Rights Reserved.

    Copyright © 2017 Provincial Health Services Authority